We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SemBioSys’ Plant-Made Biosimilar Insulin Featured on CTV News, Canada AM
News

SemBioSys’ Plant-Made Biosimilar Insulin Featured on CTV News, Canada AM

SemBioSys’ Plant-Made Biosimilar Insulin Featured on CTV News, Canada AM
News

SemBioSys’ Plant-Made Biosimilar Insulin Featured on CTV News, Canada AM

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SemBioSys’ Plant-Made Biosimilar Insulin Featured on CTV News, Canada AM"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SemBioSys Genetics Inc. has announced that its Biosimilar Insulin program was featured last night on CTV National News and this morning on Canada AM.

The news story and interview highlighted the Company’s plant-based production technology for the highly scalable manufacture of Biosimilar Insulin (SBS-1000).

In March 2009, SemBioSys announced that in a phase I/II trial SBS-1000 was deemed bioequivalent to Eli Lilly’s Humulin® R, a commercially available human insulin.

“Plants have been a source of medicine for thousands of years. The innovative nature of our plant-produced platform is drawing interest from pharmaceutical companies due to its ability to provide a low cost insulin alternative for patients that suffer from this chronic disease,” said James Szarko, President and CEO of SemBioSys Genetics Inc. “We have received new, and renewed, interest from counterparties that could potentially become international commercialization partners for our Biosimilar Insulin. We are particularly focused on developing world markets where cost-effective insulin enables access to this life-saving therapy.”
Advertisement